H.C. Wainwright analyst Yi Chen initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and $37 price target SpyGlass is a clinical-stage biopharmaceutical company focused on the development of long-acting, sustained drug delivery of approved medicines, the analyst tells investors in a research note. The firm believes the company’s bimatoprost solve the issue of patient non-compliance for prescribed topical medications, which could lead to better control of intraocular pressure.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGP:
- SpyGlass Pharma announces results from Phase 1/2 trial of BIM-IOL System
- Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
- MongoDB downgraded, Block upgraded: Wall Street’s top analyst calls
- SpyGlass Pharma: De-risked BIM-IOL Platform Poised to Reshape Glaucoma Treatment and Drive Upside to Conservative Peak Sales Estimates
- SpyGlass Pharma initiated with an Outperform at Leerink